TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27300156
Drug: Contrast treatment
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast treatment
Study: 25195684
Drug: Extracorporeal liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal liver support therapy
Study: 17767632
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume breathing using an O(2) flow of 9 l x min(‐1) for 3 min (TV x 3 min)
Study: 17767632
Drug: Four deep
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four deep breaths within 30 s using an O(2) flow of 15 l x min(‐1) (4 DB)
Study: 17767632
Drug: Eight deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight deep breaths within 1 min using an O(2) flow of 15 l x min(‐1) (8 DB)
Study: 15554760
Drug: Lamotrigine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (target dose = 200 mg/day, minimum dose = 100 mg/day)
Study: 11592671
Drug: Dextroamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (10 mg)
Study: 11592671
Drug: Dextroamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (10 mg) under no fatigue
Study: 7842531
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3 gm EPA and 2 gm DHA daily)
Study: 3585610
Drug: PMN transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMN transfusions (15 mL/kg containing 0.5 to 1.0 X 10(9) PMN, one transfusion every 12 hours for a total of five transfusions)
Study: 7774757
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (4 to 6 g/day)
Study: 7774757
Drug: High-lipase pancreatin
Normalized name: amylase / lipase / pancreatin / protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-lipase pancreatin (9 g/day)
Study: 7774757
Drug: Commercial pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial pancreatic enzyme preparations (12 to 24 tablets or 9.0 g)
Study: 7774757
Drug: Omeprazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (50 mg)
Study: 1964664
Drug: Subcutaneous fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fixed doses of a low‐molecular‐weight heparin (CY216; 225 IC anti‐Xa U/kg 12 hourly) for 10 days
Study: 1964664
Drug: Intravenous adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adjusted unfractionated heparin (UFH)
Study: 31369185
Drug: l-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-carnitine (LC) supplementation 2 g for 8 weeks
Study: 23842215
Drug: Midodrine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (12.5 mg 3 times/d; over 3 d)
Study: 22468094
Drug: tacrolimus, basiliximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus, basiliximab, and mycophenolate mofetil with steroid withdrawal
Study: 22468094
Drug: steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid treatment (control group)
Study: 8295321
Drug: Lovastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (10 mg/d)
Study: 23490655
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (n=117)
Study: 23490655
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (per-protocol analysis)
Study: 21185977
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education program (six weekly interactive lessons based on the Theory of Planned Behavior)
Study: 21185977
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (six weekly nonrelated financial lessons by mail)
Study: 17578321
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine and placebo
Study: 15489577
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered as three intravenous infusions
Study: 15489577
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (1.5 mg/kg daily for 2 weeks, followed by 1 mg/kg for 1 week, then weekly reduction of 5 mg)
Study: 11597530
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg GTN patches
Study: 8040999
Drug: Nebulised solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised solutions of saliva
Study: 8040999
Drug: Nebulised solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised solutions of isotonic saline
Study: 3141188
Drug: Percutaneous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous nitroglycerin paste (10 mg)
Study: 3141188
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (5 mg)
Study: 29110615
Drug: H2-water (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-water (300 mL per day)
Study: 28709081
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with contingency management incentives for treatment attendance (CM-Att; n=30)
Study: 26183437
Drug: Travalert dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travalert dosing aid
Study: 26183437
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of Missed Dose self-report measures
Study: 24853306
Drug: Medication possession
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication possession ratio
Study: 23918028
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous infusion
Study: 18793578
Drug: Remifentanil (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (dosing details not specified)
Study: 16414395
Drug: Pale sulfonated
Normalized name: pale dock pollen extract
DrugBank: Rumex altissimus pollen (DB10901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pale sulfonated shale oil (PSSO) 10% applied daily for 20 weeks
Study: 15282660
Drug: Recombinant platelet
Normalized name: Recombinant platelet-derived growth factor BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant platelet factor 4 (rPF4) at doses of 0.5, 1.0, 2.5, or 5.0 mg/kg
Study: 9740864
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg/d
Study: 8376914
Drug: ridogrel 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ridogrel 300 mg b.i.d.
Study: 8376914
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ridogrel 300 mg b.i.d. and ketanserin 20 mg t.i.d.
Study: 8376914
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with ridogrel and ketanserin during 3-month follow-up
Study: 22956204
Drug: Ropivacaine wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine wound infusion (0.5%)
Study: 15660547
Drug: Soft music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft music (six 45‐minute sedative music tapes) for 3 weeks
Study: 10735922
Drug: Furazolidone 200
Normalized name: furazolidone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 200 mg b.d. (RABF)
Study: 10735922
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg b.d. (RABM)
Study: 8960592
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of oral ascorbic acid
Study: 1305155
Drug: Root planing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root planing in conjunction with citric acid treatment
Study: 3895033
Drug: mesulergine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesulergine (mean dosage, 27.4 mg/d)
Study: 3895033
Drug: bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine (mean dosage, 40.8 mg/d)
Study: 24673474
Drug: Classic Antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic Antihistamines
Study: 24673474
Drug: New-generation Antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-generation Antihistamines
Study: 22925074
Drug: Flaxseed extract
Normalized name: flaxseed extract
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed extract (1 g/day, containing at least 100 mg of SDG)
Study: 22925074
Drug: Flaxseed meal
Normalized name: FLAXSEED MEAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed meal (90 g/day, containing at least 270 mg of SDG)
Study: 22925074
Drug: Collagen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen (1 g/day, placebo group)
Study: 20116706
Drug: Single-day antibiotic
Normalized name: bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-day antibiotic prophylaxis
Study: 18589558
Drug: Tacrolimus 5
Normalized name: tacrolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 5 mg capsules under fasting conditions
Study: 18589558
Drug: Tacrolimus 5
Normalized name: tacrolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 5 mg capsules under fed conditions
Study: 8116134
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus estramustine phosphate (EMP), 2 x 280 mg/day
Study: 8116134
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus flutamide, 3 x 250 mg/day
Study: 3220007
Drug: sulbactam 250
Normalized name: sulbactam 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam 250 mg plus ampicillin 500 mg intravenously
Study: 3220007
Drug: sultamicillin equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: sultamicillin equivalent to sulbactam 294 mg plus ampicillin 440 mg orally
Study: 3220007
Drug: clavulanic acid
Normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clavulanic acid 100 mg plus amoxycillin 500 mg intravenously
Study: 3220007
Drug: clavulanic acid
Normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clavulanic acid 125 mg plus amoxycillin 500 mg orally
Study: 31903588
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 0.6 μg/kg 10 min before induction followed by continuous infusion of 0.5 μg/kg/h until 1h before end of surgery)
Study: 30315206
Drug: Daily PrEP
Normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PrEP with TDF-FTC
Study: 24529292
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (wet-granulation tablet)
Study: 24529292
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (dry-granulation tablet)
Study: 21737124
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 20 μg estrogen
Study: 21737124
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 30 μg estrogen
Study: 21737124
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 35 μg estrogen
Study: 21737124
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 50 μg estrogen
Study: 11507356
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg twice a day, amoxycillin 1 g twice a day, tinidazole 500 mg twice a day (FAT group; n = 60)
Study: 11507356
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice a day, amoxycillin 1 g twice a day, tinidazole 500 mg twice a day (OAT group; n = 60)
Study: 6233550
Drug: Blo-Bag with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blo-Bag with Duovent metered dose inhaler
Study: 31436839
Drug: Nelfinavir mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir mesylate, 625 mg, twice daily
Study: 31436839
Drug: Nelfinavir mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir mesylate, 1250 mg, twice daily
Study: 20586515
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER 100-250 mg twice daily
Study: 20586515
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR 20-50 mg twice daily
Study: 10751029
Drug: Zafirlukast solution
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast solution (40 mg) administered orally
Study: 10751029
Drug: Zafirlukast solution
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast solution (40 mg) administered via oroenteric tube into the colon
Study: 10751029
Drug: Zafirlukast solution
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast solution (40 mg) administered into the distal ileum
Study: 8925829
Drug: Enalapril (ENAL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ENAL), an angiotensin converting enzyme inhibitor (ACE-I), 5 mg acute administration
Study: 23782429
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (300,000 IU cholecalciferol in oily solution administered seven days pre-operatively)
Study: 21665114
Drug: Topical cetylated
Normalized name: cetyl dimethicone Topical Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cetylated fatty ester complex (CFEC) cream application plus physical therapy (CF‐PT)
Study: 21665114
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream application plus physical therapy (PL‐PT)
Study: 10638577
Drug: Slow-release 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release 5-ASA suppositories (Pentasa 1 g/day)
Study: 10638577
Drug: Conventional 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 5-ASA suppositories (Rowasa 0.5 g b.i.d.)
Study: 26232779
Drug: 150 ml/dinner
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml/dinner dry red wine
Study: 26232779
Drug: 150 ml/dinner
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml/dinner dry red wine (among fast ethanol metabolizers)
Study: 24447498
Drug: Lower-dose tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-dose tranexamic acid regimen (loading dose of 10 mg/kg, maintenance dose of 2 mg/kg/h, pump prime dose of 40 mg)
Study: 24447498
Drug: Higher-dose tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose tranexamic acid regimen (loading dose of 30 mg/kg, maintenance dose of 16 mg/kg/h, pump prime dose of 2 mg/kg)
Study: 20380656
Drug: Dutogliptin 400
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutogliptin 400 mg
Study: 20380656
Drug: Dutogliptin 200
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutogliptin 200 mg
Study: 16117574
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy (PRP trial)
Study: 12577349
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and western medicine (TCM-WM) including cardiac diuretics, vasodilative agents, taurine, coenzyme Q10, antiarrhythmics, beta blockers, and Chinese herbal preparations such as Astragalus membranaceus and Shengmai injection.
Study: 12577349
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine alone (control group).
Study: 9713095
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment (Group 1)
Study: 9713095
Drug: Discontinuous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous treatment (Group 2)
Study: 2740841
Drug: Sucralfate in
Normalized name: Product containing sucralfate in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate in tablets
Study: 2740841
Drug: Sucralfate in
Normalized name: Product containing sucralfate in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate in suspension
Study: 31374049
Drug: Xiaoai Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoai Jiedu Decoction mimetic agent
Study: 25458464
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) treatment (2400 mg/day divided into two doses) for 4 weeks
Study: 18239389
Drug: Candesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (angiotensin II receptor antagonist)
Study: 16820564
Drug: AMI cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMI cell infusion
Study: 16820564
Drug: OMI cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMI cell infusion
Study: 12752749
Drug: Sumatriptan (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (tablet and nasal spray) and naratriptan (tablet)
Study: 9531736
Drug: Transdermal ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal ketoprofen 30 mg over the proposed surgical area twice (Group 1)
Study: 9531736
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (Group 2)
Study: 9531736
Drug: Transdermal ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal ketoprofen 30 mg over right thigh twice (Group 3)
Study: 31752976
Drug: Empirical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antimicrobial therapy
Study: 8196571
Drug: Early systemic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early systemic antifungal treatment
Study: 3065085
Drug: Tamoxifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (30 mg/day) + bromocriptine (5 mg/day)
Study: 30993313
Drug: Metformin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XL (2000 mg daily for 12 months)
Study: 29979390
Drug: Fotemustine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine at 120 mg/m biweekly
Study: 29979390
Drug: Fotemustine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine at 140 mg/m biweekly
Study: 29979390
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly schedule at 80 to 100 mg/m (not directly tested in this trial)
Study: 27123229
Drug: Desmopressin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 120 micrograms daily for 2 months, then 60 micrograms daily for 2 months, then 60 micrograms every 2 days
Study: 27123229
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg twice a day for 6 months
Study: 17305893
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 6 hours later (n=225)
Study: 17305893
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 36-48 hours later (n=225)
Study: 17305893
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 6 hours later
Study: 17305893
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 36-48 hours later
Study: 9864835
Drug: i.v. TNFR55-IgG1
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TNFR55-IgG1 0.01 mg/kg
Study: 9864835
Drug: i.v. TNFR55-IgG1
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TNFR55-IgG1 0.05 mg/kg
Study: 9864835
Drug: i.v. TNFR55-IgG1
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TNFR55-IgG1 0.1 mg/kg
Study: 9864835
Drug: i.v. TNFR55-IgG1
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TNFR55-IgG1 0.5 mg/kg
Study: 9864835
Drug: i.v. TNFR55-IgG1
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TNFR55-IgG1 20 mg biweekly
Study: 9864835
Drug: i.v. TNFR55-IgG1
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TNFR55-IgG1 50 mg monthly after loading dose of 100 mg
Study: 7890253
Drug: Ethanol (1
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1 ml/kg, 95% ethanol)
Study: 2197536
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 300 mg of pentamidine every 28 days
Study: 2197536
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of placebo (300 mg of Na isethionate) every 28 days
Study: 343479
Drug: Extradural injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural injection of 2 ml (80 mg) methyl prednisolone
Study: 343479
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 2 ml normal saline solution